Dr. Umemura is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2910 N 3rd Ave
Phoenix, AZ 85013Phone+1 734-647-8906Fax+1 734-232-4839
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Neuro-Oncology, 2015 - 2017
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Neurology, 2012 - 2015
One Brooklyn Health System/Brookdale University Hospital and Medical CenterInternship, Internal Medicine, 2011 - 2012
St. George's University School of MedicineClass of 2011
Certifications & Licensure
MI State Medical License 2017 - 2027
AZ State Medical License 2023 - 2026
NY State Medical License 2014 - 2018
NH State Medical License 2012 - 2016
PA State Medical License 2014 - 2015- American Board of Psychiatry and Neurology Neurology
- United Council for Neurologic SubspecialtiesNeuro-oncology
Clinical Trials
- Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma Start of enrollment: 2020 Aug 05
- Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response Start of enrollment: 2016 Jul 12
Roles: Contact, Principal Investigator
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- AB036. Targeting glioblastoma de-novo purine metabolism to overcome chemoradiation resistance: an interim result of phase 0/1 clinical trial in newly diagnosed and rec...Yoshie Umemura, Nathan Clarke, Wajd Al-Holou, Ameer Elaimy, Andrew Scott
Chinese Clinical Oncology. 2024-08-01 - 7 citationsONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.Isabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen
Journal of Clinical Oncology. 2024-05-01 - 1 citationsPhase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly
JCO Precision Oncology. 2024-04-01
Press Mentions
TRK Inhibitor Active in Treatment-Refractory GlioblastomaNovember 27th, 2024- Ivy Brain Tumor Center Builds on Innovative Clinical Trial Program by Appointing New Chief Medical OfficerMay 23rd, 2023
- Celebrating Women in MedicineFebruary 3rd, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
